Open AccessBook
Chronic hepatitis B : an update
Naoky C. S. Tsai,Norman Gitlin +1 more
TLDR
A group of experts in this field is assembled to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice.Abstract:
A recent Institute of Medicine report has concluded that 'there is a lack of knowledge and awareness about chronic viral hepatitis on the part of health-care and social-service providers, as well as among at-risk populations, members of the public, and policy-makers. Due to the insufficient understanding about the extent and seriousness of this public-health problem, inadequate public resources are being allocated to prevention, control, and surveillance programs'. It is with these concerns in mind that Dr. Tsai assembled a group of experts in this field to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice. Dr. Brian McMahon discusses the natural history of chronic hepatitis B with his vast knowledge and experience working with the high endemic population of Inuit in Alaska. Drs. Marc Ghany and Ed provide a very easy-to-understand description of HBV virology. Dr. Kyon-Mi Chang contributes an article on HBV immunology, which is the least understood area of this disease but has the most potential to improve our knowledge in the management of chronic hepatitis B. Dr. Anna Lok provides an authoritative review on the current issues and controversies of treatment of chronic hepatitis B. Dr. Stephen Locarnini, who has extensive experience in anti-viral resistance and its management, presents important issues in the usage of currently available anti-viral oral agents. Dr. Myron Tong discusses the current understanding of HBV carcinogenesis and updates HCC surveillance and treatment - the most dreadful outcome of this disease. Dr. Paul Martin discusses management of end- stage chronic hepatitis B - anti-viral therapy, montherapy vs combo therapy, choice of agent, when to start therapy and post-transplant patients including duration of HBIG therapy, HBcAb(+)only recipient) and Occult HBV infection. Dr. Tram Tran discusses the treatment in reproductive women, during pregnancy, and prevention of vertical transmission in third trimester with antiviral agents - an area with significant lack of good clinical evidence. Dr. Steve Han discusses management of patients with acute hepatitis B, co-infection with HDV/HCV/HIV, pre-immuno-suppressive therapy, and management of renal and heart transplant patients with HBV infection. Dr. Mei Huei Chang discusses Taiwanese success in implementing universal vaccination leading to a remarkable reduction in both prevalence of chronic hepatitis B and incidence of hepatocellular carcinoma. Finally Drs. Michelle Lai and Yun Fan Liaw provide a rundown of what we have accomplished and the hope for the future in our fight to control this disease.read more
Citations
More filters
Journal ArticleDOI
Peginterferon α in the treatment of chronic hepatitis B
TL;DR: PEG-IFN therapy is more effective for hepatitis B e antigen (HBeAg)-positive patients who have high pre-treatment alanine aminotransferase level, lower HBV DNA level and genotype A (vs genotype D), as well as those with more favourable viral predictors, such as precore stop codon or basal core promoter mutants infections in Asian patients and wild-type virus in Caucasian patients.
Journal ArticleDOI
Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC
Vicki Wing-Ki Hui,Stephen L. Chan,Vincent Wai-Sun Wong,Lilian Yan Liang,Terry Cheuk-Fung Yip,Jimmy Che-To Lai,Becky Wing-Yan Yuen,Hester Wing-Sum Luk,Yee-Kit Tse,Hye Won Lee,Henry Lik-Yuen Chan,Grace Lai-Hung Wong +11 more
TL;DR: The uptake of antiviral treatment in HCC patients increased over the past decade and it is never too late to initiate NA treatment, even after HCC diagnosis, which contributed mostly to the uptake rate.
Journal ArticleDOI
Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir.
Wai-Kay Seto,Kevin Liu,James Fung,Danny Ka-Ho Wong,John Chi-Hang Yuen,Ivan Hung,Ching-Lung Lai,Man-Fung Yuen +7 more
TL;DR: Week 24 HBV DNA<200 IU/ml was predictive of favourable long-term virological outcomes and could be used to assist treatment decisions on continuing lamivudine and adefovir or switching to more potent therapy.
Journal ArticleDOI
Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection.
Won Mook Choi,Jeong Hoon Lee,Hongkeun Ahn,Hyeki Cho,Young Youn Cho,Minjong Lee,Jeong-Ju Yoo,Yuri Cho,Dong Hyeon Lee,Yun Bin Lee,Eun Ju Cho,Su Jong Yu,Nam-Joon Yi,Kwang-Woong Lee,Yoon Jun Kim,Jung Hwan Yoon,Kyung-Suk Suh,Chung Yong Kim,Hyo Suk Lee +18 more
TL;DR: This study aimed to investigate whether noninvasive fibrosis indices could predict intrahepatic recurrence and death after curative resection of HCC.
Journal ArticleDOI
Cost-Effectiveness Analysis of Antiviral Treatments for HBeAg-Positive Chronic Hepatitis B in Canada
Jing He,Jing He,Jing He,James M. Bowen,James M. Bowen,Feng Xie,Feng Xie,Ron Goeree,Ron Goeree +8 more
TL;DR: Tenofovir generated the best results compared with all other therapies under evaluation, and over the 72-year period of the model, the expected life expectancy of lamivUDine, telbivudine, entecavir, and ten ofovir was 35.71 years, which is significantly lower than that for lamvudine.